CSIMarket


Genocea Biosciences Inc   (GNCA)
Other Ticker:  
 


 

Genocea Biosciences Inc

GNCA's Financial Statements and Analysis



Genocea Biosciences Inc increased first quarter of 2022 net loss per share of $-0.22 compare to net loss per share of $-0.17 recorded in the same quarter a year ago a decrease compare to $-0.19 realized in previous quarter.


first quarter of 2022
Earnings Per Share Revenues
$ -0.22 $  0 Mill
$-0.05     $-1M     -68.38 %



Genocea Biosciences Inc 's Revenue fell by -68.38 % in first quarter of 2022 (Mar 31 2022) year on year, to $0 million and declined by -30.23 % sequentially.


Genocea Biosciences Inc is

More on GNCA's Income Statement



Genocea Biosciences Inc 's in thefirst quarter of 2022 recorded net loss of $-15.978 million, an increase from net loss of $-11.983 million in I. Quarter a year ago.

Sequentially net loss advanced

More on GNCA's Growth

Genocea Biosciences Inc Inventories
In Mar 31 2022 company's net cash and cash equivalents decreased by $-17 million, capital expenditures grew by -1.109-13.35%, to $-1 millions compare to same quarter a year ago

More on GNCA's Cash flow Statement


Genocea Biosciences Inc does not pay out common stock dividend.

In trailing twelve-month period Genocea Biosciences Inc payed $ -0.68 cash per share, on a free-cash flow basis .

Book value fell by -54.74 % sequentially to $0.17 per share, -31.98% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value grew to $ 0.17 per share from $ 0.03.

Company issued 0.76 million shares or 1.07 % in Mar 31 2022.


More on GNCA's Dividends

 Market Capitalization (Millions) 0
 Shares Outstanding (Millions) 71
 Total Debt (Millions $) 8
 Revenue (TTM) (Millions $) 21
 Net Income (TTM) (Millions $) -37
 Cash Flow (TTM) (Millions $) -46
 Capital Exp. (TTM) (Millions $) -3
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -




Genocea Biosciences Inc does not pay out common stock dividend.

In trailing twelve-month period Genocea Biosciences Inc had negative $ -0.68 cash flow per share, on a free-cash flow basis .

Book value fell by -54.74 % sequentially to $0.17 per share, -31.98% of net loss per share in trailing twelve-month period were subtructed from shareholder value.
Tangible Book value grew to $ 0.17 per share from $ 0.03.

Company issued 0.76 million shares or 1.07 % in Mar 31 2022.


More on GNCA's Balance Sheets

 Market Capitalization (Millions) 0
 Shares Outstanding (Millions) 71
 Total Debt (Millions $) 8
 Revenue (TTM) (Millions $) 21
 Net Income (TTM) (Millions $) -37
 Cash Flow (TTM) (Millions $) -46
 Capital Exp. (TTM) (Millions $) -3
 Dividend TTM ($) 0 $
 Dividend Yield TTM (%) -
 Employees (TTM) $ -
   



Date modified: 2023-03-25T04:00:08+00:00





Help

About us

Advertise

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research. 
   Copyright © 2024 CSIMarket, Inc. All rights reserved. This site uses cookies to make your browsing experince better. By using this site, you agree to the Terms of Service and Privacy Policy - UPDATED (Read about our Privacy Policy)

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com